Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

The drugs cyclosporine A (CsA) and tacrolimus (FK506) revolutionized organ transplantation. Both compounds are still widely used in the clinic as well as for basic research, even though they have dramatic side effects and modulate other pathways than calcineurin-NFATc, too. To answer the major open question - whether the adverse side effects are secondary to the actions of the drugs on the calcineurin-NFATc pathway - alternative inhibitors were developed. Ideal inhibitors should discriminate between the inhibition of (i) calcineurin and peptidyl-prolyl cis-trans isomerases (PPIases; the matchmaker proteins of CsA and FK506), (ii) calcineurin and the other Ser/Thr protein phosphatases, and (iii) NFATc and other transcription factors. In this review we summarize the current knowledge about novel inhibitors, synthesized or identified in the last decades, and focus on their mode of action, specificity, and biological effects

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely

Assessing ecological resilience to human induced environmental change in shallow lakes

Sudden unpredictable changes in ecosystems are an increasing source of concern because of their inherent unpredictability and the difficulties involved in restoration. Our understanding of the changes that occur across different trophic levels and the form of this change is lacking. This is especially true of large shallow lakes, where characteristics such as fetch and depth are close to theoretical boundary values for hysteretic behaviour. The development of reliable indicators capable of predicting these changes has been the focus of much research in recent years. The success of these early warning indicators (EWIs) has so far been mixed. There remain many unknowns about how they perform under a wide variety of conditions and parameters. Future climate change is predicted to have a wide range of impacts through the interaction of combined pressures, making the understanding of EWIs and the in-lake processes that occur during regime shifts imperative. Loch Leven, Scotland, UK, is a large shallow lake with a history of eutrophication, research and management and as such is an ideal study site to better understand resilience and regime shifts under a range of interacting stressors. The objectives of this research are to: (1) analyse long term data to identify the occurrence of common tipping points within the chemical (water column nutrient concentrations) and biological (macrophytes, phytoplankton, zooplankton) components of the loch, then test these tipping points using five statistical early warning indicators (EWIs) across multiple rolling window sizes; and (2) quantify the changes in lake ecology using a before/after analysis and testing for non-linearity, combined with modelling using the aquatic ecosystem process model PCLake to determine the level of resilience following a regime shift during recovery from eutrophication; (3) using PCLake, examine the sensitivity of Loch Leven to regime shifts in the face of predicted environmental change (e.g. climate change, nutrient pollution). Statistical analysis identified tipping points across all trophic levels included, from physical and chemical variables through to apex predators. The success of EWIs in predicting the tipping points was highly dependent on the number of EWIs used, with window size having a smaller impact. The 45% window size had the highest overall accuracy across all EWIs but only detected 16.5% more tipping points than the window size with the lowest overall accuracy. Differences between individual EWI performance and usage of them as a group was substantial with a 29.7% increase between the two. In both individual and group use of EWIs, false positives (early warning without a tipping point) were more common than true positives (tipping point preceded by EWI), creating significant doubts about their reliability as management tools. Significant change was seen across multiple variables and trophic levels in the before/after analysis following sudden recovery from eutrophication, with most variables also showing evidence of non-linear change. Modelling of responses to nutrient loading for chlorophyll, zooplankton and macrophytes, under states from before and after the shift, indicate hysteresis and thus the presence of feedback mechanisms. The modelling of responses to nutrient loading and predicted climate change in temperature and precipitation demonstrated that increases in temperature and decreases in summer precipitation individually had large impacts on chlorophyll and zooplankton at medium to high phosphorus (P) loads. However, modelling of the combined effects of these changes resulted in the highest lake chlorophyll concentrations of all tested scenarios. At low P loads higher temperatures and increased winter precipitation had the greatest impact on system resilience with a lower Critical Nutrient Load (CNL). The difference between chlorophyll and zooplankton as opposed to macrophytes was in the presence of a lower CNL for the increased winter precipitation-only scenarios which was not seen in the macrophytes. This highlights the potential role of high winter inputs potentially loaded with particulate matter in reducing resilience at lower P loads. This research has highlighted the vulnerability and low resilience of Loch Leven to environmental change. The presence of multiple tipping points and high levels of EWI activity show a high level of flexibility in the system. Coupled with the occurrence of widespread trophic change during a sudden recovery and a small level of hysteresis and high levels of sensitivity to climate change, the low levels of resilience become clear. The impact of lake-specific characteristics such as moderate depth, large fetch and a heterogeneous bed morphology is particularly evident in the limitations on macrophyte cover and the reliance on zooplankton to determine the hysteresis offset (amount of phosphorus (P) loading between the two CNL). The presence of these characteristics can be used to identify other lakes vulnerable to change. Improving the predictive capabilities of resilience indicators such as EWIs, and better understanding of the ecological changes that occur during non-linear change in response to recovery and climate change, can help target relevant ecosystem components for preventative management. These actions may become necessary under even the most conservative estimates of environmental change

CropPol: a dynamic, open and global database on crop pollination

This is the final version. Available from Wiley via the DOI in this record The original dataset (v1.1.0) of the CropPol database can be accessed from the ECOLOGY repository. Main upgrades of these datasets will be versioned and deposited in Zenodo (DOI: 10.5281/zenodo.5546600)Data availability. V.C. Computer programs and data-processing algorithms: The algorithms used in deriving, processing, or transforming data can be accessed in the DataS1.zip file and the Zenodo repository (DOI: 10.5281/zenodo.5546600). V.D. Archiving: The data is archived for long-term storage and access in Zenodo (DOI: 10.5281/zenodo.5546600)Seventy five percent of the world's food crops benefit from insect pollination. Hence, there has been increased interest in how global change drivers impact this critical ecosystem service. Because standardized data on crop pollination are rarely available, we are limited in our capacity to understand the variation in pollination benefits to crop yield, as well as to anticipate changes in this service, develop predictions, and inform management actions. Here, we present CropPol, a dynamic, open and global database on crop pollination. It contains measurements recorded from 202 crop studies, covering 3,394 field observations, 2,552 yield measurements (i.e. berry weight, number of fruits and kg per hectare, among others), and 47,752 insect records from 48 commercial crops distributed around the globe. CropPol comprises 32 of the 87 leading global crops and commodities that are pollinator dependent. Malus domestica is the most represented crop (32 studies), followed by Brassica napus (22 studies), Vaccinium corymbosum (13 studies), and Citrullus lanatus (12 studies). The most abundant pollinator guilds recorded are honey bees (34.22% counts), bumblebees (19.19%), flies other than Syrphidae and Bombyliidae (13.18%), other wild bees (13.13%), beetles (10.97%), Syrphidae (4.87%), and Bombyliidae (0.05%). Locations comprise 34 countries distributed among Europe (76 studies), Northern America (60), Latin America and the Caribbean (29), Asia (20), Oceania (10), and Africa (7). Sampling spans three decades and is concentrated on 2001-05 (21 studies), 2006-10 (40), 2011-15 (88), and 2016-20 (50). This is the most comprehensive open global data set on measurements of crop flower visitors, crop pollinators and pollination to date, and we encourage researchers to add more datasets to this database in the future. This data set is released for non-commercial use only. Credits should be given to this paper (i.e., proper citation), and the products generated with this database should be shared under the same license terms (CC BY-NC-SA). This article is protected by copyright. All rights reserved.OBServ Projec

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Cutting-Edge of RFID: Guest Editorial on Augmented RFID Sensing and Robot Navigation Systems

The year 2023 was extremely fruitful for RFID community as it offered a diverse range of perspectives, methodologies, and findings, among all the spectrum of RFID communications and systems. In this context, the IEEE JOURNAL OF RADIO FREQUENCY IDENTIFICATION took the opportunity to gather new florid research contributions in the field of RFID technology in two special issues devoted to hot and cutting-edge research topics: "Augmented RFID sensing systems for environment, healthcare and safety" and "RFID Sensor Fusion for Navigation of Robots and Vehicles". Sensing capabilities and location-awareness, especially focused to the development of autonomous robots, represent two vital applications for the development of next-generation industrial systems, technologies that serve people and communities. In Fig. 1 it is depicted the output of an online search on the IEEE XPLORE database by selecting only papers published in journals (journals + magazines + early access) from 2015 to 2022, with focus on "RFID Sensing" (blue bars) and "RFID localization" (red bars). There is a clear trend of growth in recent years, which highlights the topicality of the journal proposed special issues in selecting themes of interest to the community. Furthermore, the special issue aimed to emphasize the requirements of industries associated with these systems and to encourage research towards exploring innovative solutions for commercial applications. The articles featured in this special issue offer a diverse range of perspectives, methodologies, and findings, also highlighting the multidisciplinary nature of RFID

Cutting-Edge of RFID: Guest Editorial on Augmented RFID Sensing and Robot Navigation Systems

The year 2023 was extremely fruitful for RFID community as it offered a diverse range of perspectives, methodologies, and findings, among all the spectrum of RFID communications and systems. In this context, the IEEE JOURNAL OF RADIO FREQUENCY IDENTIFICATION took the opportunity to gather new florid research contributions in the field of RFID technology in two special issues devoted to hot and cutting-edge research topics: "Augmented RFID sensing systems for environment, healthcare and safety" and "RFID Sensor Fusion for Navigation of Robots and Vehicles". Sensing capabilities and location-awareness, especially focused to the development of autonomous robots, represent two vital applications for the development of next-generation industrial systems, technologies that serve people and communities. In Fig. 1 it is depicted the output of an online search on the IEEE XPLORE database by selecting only papers published in journals (journals + magazines + early access) from 2015 to 2022, with focus on "RFID Sensing" (blue bars) and "RFID localization" (red bars). There is a clear trend of growth in recent years, which highlights the topicality of the journal proposed special issues in selecting themes of interest to the community. Furthermore, the special issue aimed to emphasize the requirements of industries associated with these systems and to encourage research towards exploring innovative solutions for commercial applications. The articles featured in this special issue offer a diverse range of perspectives, methodologies, and findings, also highlighting the multidisciplinary nature of RFID